# Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors

> **NCT06950697** · — · RECRUITING · sponsor: **Beijing Chao Yang Hospital** · enrollment: 2400 (estimated)

## Conditions studied

- Lung Cancer
- Venous Thromboembolism
- Arterial Thromboembolism
- Immune Checkpoint Inhibitors (ICIs)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT06950697
- **Lead sponsor:** Beijing Chao Yang Hospital
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2019-01-01
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-12-01
- **Target enrollment:** 2400 (ESTIMATED)
- **Last updated:** 2026-04-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06950697

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06950697, "Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT06950697. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*